迈向个体化医疗:脓毒症免疫治疗的范围综述
该范围综述检索PubMed、Embase、Cochrane CENTRAL和ClinicalTrials.gov至2024年1月29日,共15,853项研究,最终纳入771项(282项观察性、489项干预性),评估成人脓毒症免疫调节治疗。个体化方法(按变量界值分亚组或数据驱动分亚表型以免疫特征指导治疗)仅见于70项研究(9%),富集策略采用温度、实验室、生物标志物或遗传变量界值。试验结果常相互矛盾,可能因缺乏患者分层或严重程度与时机影响免疫调节治疗结果;采用个体化方法时,若干干预显现临床获益趋势,作者认为这为未来个体化免疫治疗临床试验带来希望。
要点
- 纳入771项成人脓毒症免疫调节研究,仅70项(9%)采用个体化方法(亚组或亚表型指导治疗)。
- 个体化富集策略使用温度、实验室、生物标志物或遗传变量的界值对患者分类。
- 试验结果常相互矛盾,原文认为可能因缺乏患者分层或严重程度与时机的影响。
- 采用个体化方法时,若干干预显现临床获益趋势,作者认为这为未来个体化免疫治疗试验带来希望。
- 纳入研究涵盖针对先天免疫反应、补体系统、凝血与内皮功能障碍、非药物治疗、多效药物、免疫营养、合并治疗、中医药、免疫刺激细胞因子与生长因子、静脉免疫球蛋白、间充质干细胞和免疫检查点抑制剂的治疗组。
适用人群与场景
- 成人脓毒症患者;纳入随机对照试验和队列研究,评估免疫调节治疗。
诊断标准与关键阈值
- 个体化免疫治疗定义为将患者分类至特定亚组或亚表型,并以患者免疫特征指导治疗;亚组基于任一变量界值,亚表型基于数据驱动评估可靠区分。
研究设计与关键结果
- 范围综述检索PubMed、Embase、Cochrane CENTRAL和ClinicalTrials.gov,从最早可获取论文至2024年1月29日,共15,853项研究,标题摘要筛选后1409项(9%)进入资格评估,最终纳入771项,其中观察性282项(37%)、干预性489项(63%)。
- 治疗组涵盖针对先天免疫反应、补体系统、凝血与内皮功能障碍、非药物治疗、多效药物、免疫营养、合并治疗、中医药、免疫刺激细胞因子与生长因子、静脉免疫球蛋白、间充质干细胞和免疫检查点抑制剂的治疗。
- 个体化方法纳入70项研究(9%);富集采用温度、实验室、生物标志物或遗传变量的界值。
- 试验结果常相互矛盾,原文认为可能因缺乏患者分层或严重程度与时机对免疫调节治疗结果的影响;采用个体化方法时,若干干预显现临床获益趋势。
证据类型、等级与局限
- 证据类型:范围综述,纳入随机对照试验和队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,采用个体化方法时若干干预显现的临床获益趋势为未来个体化免疫治疗临床试验带来希望。
- 原文指出试验结果常相互矛盾,可能因缺乏患者分层或严重程度与时机的影响,提示解读免疫调节治疗试验时需考虑分层与时机。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Despite significant progress in our understanding of the pathophysiology of sepsis and extensive clinical research, there are few proven therapies addressing the underlying immune dysregulation of this life-threatening condition. The aim of this scoping review is to describe the literature evaluating immunotherapy in adult patients with sepsis, emphasizing on methods providing a "personalized immunotherapy" approach, which was defined as the classification of patients into a distinct subgroup or subphenotype, in which a patient's immune profile is used to guide treatment. Subgroups are subsets of sepsis patients, based on any cut-off in a variable. Subphenotypes are subgroups that can be reliably discriminated from other subgroup based on data-driven assessments. Included studies were randomized controlled trials and cohort studies investigating immunomodulatory therapies in adults with sepsis. Studies were identified by searching PubMed, Embase, Cochrane CENTRAL and ClinicalTrials.gov, from the first paper available until January 29th, 2024. The search resulted in 15,853 studies. Title and abstract screening resulted in 1409 studies (9%), assessed for eligibility; 771 studies were included, of which 282 (37%) were observational and 489 (63%) interventional. Treatment groups included were treatments targeting the innate immune response, the complement system, coagulation and endothelial dysfunction, non-pharmalogical treatment, pleiotropic drugs, immunonutrition, concomitant treatments, Traditional Chinese Medicine, immunostimulatory cytokines and growth factors, intravenous immunoglobulins, mesenchymal stem cells and immune-checkpoint inhibitors. A personalized approach was incorporated in 70 studies (9%). Enrichment was applied using cut-offs in temperature, laboratory, biomarker or genetic variables. Trials often showed conflicting results, possibly due to the lack of patient stratification or the potential influence of severity and timing on immunomodulatory therapy results. When a personalized approach was applied, trends of clinical benefit for several interventions emerged, which hold promise for future clinical trials using personalized immunotherapy.
参考来源
- Slim MA, van Mourik N, Bakkerus L, et al. Towards personalized medicine: a scoping review of immunotherapy in sepsis. Crit Care. 2024. PMID: 38807151. doi:10.1186/s13054-024-04964-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。